{"product_id":"harmonybiosciences-business-model-canvas","title":"Harmony Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarmony's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Harmony's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony Biosciences actively pursues research and development collaborations with leading academic institutions, innovative biotechnology firms, and specialized research organizations. These partnerships are fundamental to deepening Harmony's comprehension of rare neurological diseases and expediting the identification of novel therapeutic compounds. For instance, in 2024, Harmony announced a significant collaboration with the Broad Institute to explore advanced genomic sequencing techniques for identifying novel therapeutic targets in amyotrophic lateral sclerosis (ALS). This strategic alliance allows Harmony to tap into external expertise and state-of-the-art scientific progress, especially in rapidly evolving fields such as gene therapy and precision medicine.\u003c\/p\u003e\n\u003cp\u003eThese vital collaborations provide Harmony with access to promising new drug candidates and cutting-edge technologies, effectively expanding its therapeutic pipeline beyond its current core areas of focus. By engaging with external innovators, Harmony can accelerate its discovery timelines and de-risk early-stage research. In 2023, Harmony's partnership with a specialized AI drug discovery company led to the identification of three promising preclinical candidates, demonstrating the tangible benefits of such strategic research alliances.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Acquisition Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony's strategic partnerships are crucial for portfolio expansion, often taking the form of licensing and acquisition agreements.  For example, the acquisition of Epygenix Therapeutics, Inc. bolstered Harmony's pipeline with a rare epilepsy franchise. \u003c\/p\u003e\n\u003cp\u003eFurthermore, a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (BP1.15205) demonstrates a targeted approach to acquiring promising assets. These collaborations are key to securing exclusive rights for developing and commercializing novel therapies across various markets, accelerating growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony heavily leverages Contract Research Organizations (CROs) for critical functions like conducting clinical trials, managing vast amounts of data, and navigating complex regulatory landscapes for its drug development initiatives.  These collaborations are essential for accessing specialized expertise and resources, enabling Harmony to move its pipeline forward efficiently through various stages of clinical evaluation.\u003c\/p\u003e\n\u003cp\u003eThe global CRO market is substantial, with projections indicating continued growth. For instance, the market was valued at approximately $50 billion in 2023 and is expected to see a compound annual growth rate (CAGR) of around 7-8% leading up to 2028, demonstrating the significant investment in these services.  This reliance on CROs allows Harmony to maintain flexibility and scale its research efforts effectively.\u003c\/p\u003e\n\u003cp\u003eCROs are indispensable in the demanding process of bringing new therapies to market. They ensure that clinical studies are conducted with the highest ethical standards and scientific rigor, a crucial element for regulatory approval and patient safety.  Harmony's strategic partnerships with leading CROs underscore their commitment to a robust and compliant drug development pathway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarmony's key partnerships with healthcare providers and institutions are foundational to its business model. Collaborating with hospitals, specialized clinics, and individual healthcare professionals (HCPs) is essential for identifying patients, enrolling them in clinical trials, and facilitating the prescription and administration of Harmony's therapies. This broad engagement strategy extends to HCPs who may not currently participate in existing REMS programs, aiming to significantly expand patient access to treatments.\u003c\/p\u003e\n\u003cp\u003eThese vital relationships ensure that individuals suffering from rare neurological diseases receive accurate diagnoses and the most appropriate treatment options available. For instance, in 2024, Harmony continued to build its network of prescribers, with a focus on expanding reach beyond established oxybate prescribers to capture a wider patient population.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital Systems:\u003c\/strong\u003e Partnerships with major hospital networks allow for streamlined patient identification and access to Harmony's treatments within integrated care settings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialty Clinics:\u003c\/strong\u003e Collaborations with clinics specializing in neurology and rare diseases are crucial for reaching targeted patient groups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndividual Healthcare Professionals:\u003c\/strong\u003e Engaging with a diverse range of physicians and specialists ensures broad prescription reach, including those outside of existing REMS programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trial Sites:\u003c\/strong\u003e Partnerships with institutions that conduct clinical trials are vital for Harmony's research and development pipeline, facilitating patient recruitment and data collection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Foundations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarmony's partnerships with patient advocacy groups and foundations are vital for grasping unmet patient needs and boosting disease awareness. These collaborations are instrumental in ensuring patients can access necessary therapies. In 2024, patient advocacy groups continued to be a cornerstone for gathering insights into the patient journey, enabling Harmony to craft more patient-centric programs and educational campaigns.\u003c\/p\u003e\n\u003cp\u003eThese partnerships also empower policy advocacy for rare disease patients. For instance, by working with organizations like the National Organization for Rare Disorders (NORD), which represents over 300 patient organizations, Harmony can contribute to shaping policies that improve treatment accessibility and research funding. This collaborative approach ensures that Harmony’s strategies remain aligned with the evolving needs of the patient community.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnderstanding Unmet Needs:\u003c\/strong\u003e Patient advocacy groups provide direct feedback on the challenges faced by individuals with specific conditions, guiding Harmony's research and development priorities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisease Awareness Campaigns:\u003c\/strong\u003e Collaborations with foundations help to amplify public understanding of rare diseases, fostering a more supportive environment for patients and encouraging early diagnosis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access Support:\u003c\/strong\u003e These partnerships are crucial for developing programs that assist patients in navigating insurance complexities and accessing Harmony's treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy Advocacy:\u003c\/strong\u003e Working with advocacy groups, Harmony supports efforts to influence legislation that benefits rare disease patients, such as improved reimbursement policies and research incentives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships Accelerate Rare Disease Therapy Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships for Harmony Biosciences are crucial for advancing its rare disease pipeline and ensuring patient access to therapies. These include collaborations with academic institutions and biotech firms for R\u0026amp;D, as seen in their 2024 alliance with the Broad Institute for ALS research. Furthermore, licensing and acquisition deals, like the purchase of Epygenix Therapeutics, expand their drug portfolio. Harmony also heavily relies on Contract Research Organizations (CROs), a market valued at approximately $50 billion in 2023, to manage clinical trials and regulatory processes efficiently.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA dynamic framework that visualizes and analyzes a company's strategy by detailing its customer segments, value propositions, channels, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eIt provides a holistic view of how a business creates, delivers, and captures value, enabling strategic planning and innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Harmony Business Model Canvas alleviates the pain of fragmented strategy by providing a unified, visual representation of all key business elements.\u003c\/p\u003e\n\u003cp\u003eIt resolves the struggle of unclear direction by offering a single, coherent framework that aligns every aspect of the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony's central engine is its robust Research and Development (R\u0026amp;D) aimed at pioneering treatments for rare neurological disorders. This encompasses everything from early-stage preclinical investigations and innovative drug discovery to the meticulous management of a diverse clinical trial portfolio.  The company is actively pursuing new indications and improved formulations for conditions like Fragile X syndrome, idiopathic hypersomnia, and several forms of epilepsy.\u003c\/p\u003e\n\u003cp\u003eThis dedication to R\u0026amp;D is clearly demonstrated by Harmony's financial performance.  In the first quarter of 2025, R\u0026amp;D expenditures saw a substantial increase, underscoring the company's commitment to advancing its pipeline and bringing novel therapies to patients.  This strategic investment is crucial for maintaining their competitive edge in the specialized field of rare neurological diseases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trials management is Harmony's core operational activity, encompassing patient recruitment, data collection, and rigorous monitoring to ensure drug safety and efficacy.  This critical process underpins the development of new therapeutic candidates.\u003c\/p\u003e\n\u003cp\u003eHarmony is actively engaged in multiple Phase 3 trials, a significant investment in advancing its pipeline.  Notable among these are studies for ZYN002 targeting Fragile X syndrome, alongside trials for improved pitolisant formulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing and supply chain management are central to ensuring patients consistently receive high-quality WAKIX and future therapies. This encompasses everything from sourcing essential raw materials to the final distribution of the drug product, directly impacting patient accessibility and treatment continuity.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Idorsia Pharmaceuticals, the developer of WAKIX, reported net sales of CHF 174.1 million for the drug, highlighting the significant operational effort required to bring this therapy to market and manage its global supply chain effectively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarmony's commercialization strategy for WAKIX centers on direct engagement with healthcare providers. This includes robust marketing campaigns and a dedicated sales force focused on educating physicians about the therapeutic benefits of WAKIX for conditions like narcolepsy. Their efforts aim to ensure broad physician adoption and patient access.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Harmony reported $123.4 million in selling, general, and administrative expenses, a significant portion of which is dedicated to these commercialization and sales activities. This investment underpins their commitment to building market presence and driving WAKIX adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Education:\u003c\/strong\u003e Harmony actively educates healthcare professionals on WAKIX's efficacy and patient profile through medical conferences, publications, and direct outreach.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force Deployment:\u003c\/strong\u003e A specialized sales team engages directly with physicians and pharmacists to facilitate prescription and dispensing of WAKIX.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Network:\u003c\/strong\u003e Ensuring widespread availability, Harmony manages the distribution of WAKIX to pharmacies and healthcare facilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Initiatives:\u003c\/strong\u003e Efforts are made to secure favorable formulary placement and reimbursement for WAKIX to improve patient access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating the intricate web of regulatory pathways is a cornerstone of Harmony's operations. This involves meticulous preparation and submission of crucial documents like New Drug Applications (NDAs) and Supplemental New Drug Applications (sNDAs) to health authorities.  The company is actively engaged in managing these processes for its entire drug pipeline, with a specific focus on an upcoming sNDA submission for pitolisant in the treatment of idiopathic hypersomnia.\u003c\/p\u003e\n\u003cp\u003eEnsuring continuous adherence to evolving health authority regulations is paramount. Harmony's commitment to ongoing compliance safeguards its product development and market access. For instance, in 2024, the pharmaceutical industry saw significant regulatory shifts, with the FDA approving a record number of novel drugs, underscoring the importance of robust regulatory affairs departments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Pathway Navigation\u003c\/strong\u003e: Successfully guiding new drug candidates through complex approval processes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplication Submissions\u003c\/strong\u003e: Preparing and filing NDAs and sNDAs with regulatory bodies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOngoing Compliance Management\u003c\/strong\u003e: Maintaining adherence to all post-approval health authority requirements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Regulatory Oversight\u003c\/strong\u003e: Managing regulatory aspects for all investigational and approved products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePivotal Activities: Pioneering Neurological Disorder Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony's key activities revolve around pioneering research and development for rare neurological disorders, meticulously managing clinical trials, and ensuring efficient manufacturing and supply chain operations for its therapies. The company also focuses on robust commercialization strategies, including direct engagement with healthcare providers and market access initiatives, while navigating complex regulatory pathways for drug approvals and ongoing compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Data\/Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003ePioneering treatments for rare neurological disorders, from preclinical to clinical trials.\u003c\/td\u003e\n\u003ctd\u003eActively pursuing new indications and improved formulations for conditions like Fragile X syndrome and epilepsy. R\u0026amp;D expenditures saw a substantial increase in Q1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials Management\u003c\/td\u003e\n\u003ctd\u003ePatient recruitment, data collection, and monitoring for drug safety and efficacy.\u003c\/td\u003e\n\u003ctd\u003eEngaged in multiple Phase 3 trials, including those for ZYN002 (Fragile X syndrome) and improved pitolisant formulations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eSourcing raw materials to final distribution, ensuring consistent drug supply.\u003c\/td\u003e\n\u003ctd\u003eManaging the global supply chain for WAKIX, aiming for patient accessibility and treatment continuity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eDirect engagement with healthcare providers, marketing, and sales force deployment.\u003c\/td\u003e\n\u003ctd\u003eIn 2023, SG\u0026amp;A expenses were $123.4 million, largely supporting these activities to drive WAKIX adoption.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eNavigating regulatory pathways, submitting applications (NDAs, sNDAs), and ensuring compliance.\u003c\/td\u003e\n\u003ctd\u003eFocus on an upcoming sNDA submission for pitolisant in idiopathic hypersomnia. Industry saw record drug approvals in 2024, highlighting regulatory importance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Harmony Business Model Canvas preview you're viewing is the exact document you will receive upon purchase. This means you're seeing a direct snapshot of the final, complete file, ensuring full transparency and no surprises. Upon completing your order, you'll gain immediate access to this professionally structured and ready-to-use Business Model Canvas, identical to what you see here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611251196281,"sku":"harmonybiosciences-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harmonybiosciences-business-model-canvas.png?v=1754753804","url":"https:\/\/growthsharematrix.com\/products\/harmonybiosciences-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}